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ABSTRACT Polymerase chain reaction (PCR) DNA quan-
titation (PDQ) susceptibility testing rapidly and directly mea-
sures nucleoside sensitivity of human immunodeficiency virus
type 1 (HIV-1) isolates. PCR is used to quantitate the amount
of HIV-1 DNA synthesized after in vitro infection of peripheral
blood mononuclear cells. The relative amounts of HIV-1 DNA
in cell lysates from cultures maintained at different drug
concentrations reflect drug inhibition of virus replication. The
results ofPDQ susceptibility testing of 2- or 3-day cultures are
supported by assays measuring HIV-1 p24 antigen production
in supernatants of 7- or 10-day cultures. DNA sequence anal-
yses to identify mutations in the reverse transcriptase gene that
cause resistance to 3'-azido-3'-deoxythymidine also support the
PDQ results. With the PDQ method, both infectivity titration
and susceptibility testing can be performed on supernatants
from primary cultures of peripheral blood mononuclear cells.
PDQ susceptibility testing should facilitate epidemiologic stud-
ies of the clinical significance of drug-resistant HIV-1 isolates.
Human immunodeficiency virus type 1 (HIV-1) isolates re-
sistant to zidovudine (3'-azido-3'-deoxythymidine, AZT) and
didanosine (2',3'-dideoxyinosine, ddl) have been reported,
but the role of drug-resistant HIV-1 in pathogenesis is not
well defined (1-3). Rapid, quantitative drug susceptibility
testing of all isolates, and not only the minority that replicate
in MT-2 cells (1, 4), is necessary for epidemiologic evaluation
of the contribution of resistant HIV-1 to disease progression.
To obtain an HIV-1 isolate from virtually every subject, each
HIV-1-infected subject's peripheral blood mononuclear cells
(PBMCs) must be cocultivated with an uninfected donor's
phytohemagglutinin (PHA)-stimulated PBMCs. We have de-
veloped a rapid method for drug susceptibility testing that
allows the use of the supernatants of such primary cocul-
tures. The polymerase chain reaction (PCR) is used to
determine relative amounts of HIV-1 DNA in cultures main-
tained in different drug concentrations following in vitro
infection. The results of this PCR DNA quantitation (PDQ)
susceptibility testing are supported by HIV-1 p24 antigen-
based susceptibility assays (5) and by DNA sequencing of
codons in the HIV-1 reverse transcriptase (RT) gene in which
specific mutations cause AZT resistance (2).
MATERIALS AND METHODS
Cell and Virus Culture. Primary PBMC coculture super-
natants were used. These were in excess of those stored for
use in virologic assessment of clinical protocols. Primary
coculture of HIV-1 was performed with 5 x 106 3-day PHA
(10 gg/ml; Difco)-stimulated PBMCs from a single HIV-1-
seronegative blood donor and 10 x 106 PBMCs (or 1 ml of
plasma) from an HIV-1-infected subject (5). Virus stocks
were generated from passage of primary coculture superna-
tants on PHA-stimulated PBMCs (5).
Prior to each PDQ experiment, virus inocula were first
filtered (Millex HV, 0.45 ,um, Millipore) and then treated with
RQ1 RNase-free DNase (Promega) in 1 mM MgCl2 (4 units of
DNase per ml of culture supernatant) for 20 min at room
temperature. Heat-inactivated (70'C, 30 min) virus inoculum
served as a control for the adequacy of filtering and DNase
treatment in eliminating input HIV-1 DNA (6).
PDQ HIV-1 Infectivity Titration. Aliquots (150 1LI) of serial
dilutions of virus sample were used to infect 2 x 106 PHA-
stimulated donor PBMCs in 1.5 ml of growth medium (5) per
well of a flat-bottom 24-well plate (Corning). Separate cell
samples were counted, harvested, and lysed at 48, 72, and 96
hr. Quantitative PCR and HIV-1 copy-number determination
were then performed in duplicate on each lysate.
PDQ Susceptibility Testing. The results of aPDQ infectivity
titration assay were used to determine the virus dilution and
length of culture time employed in a subsequent PDQ sus-
ceptibility test. These parameters were chosen so that the
yield of HIV-i-specific PCR product for the untreated control
infection would fall on the HIV-1 copy-number standard
curve before the curve approached its asymptotic maximum,
or plateau. PHA-stimulated donor PBMCs were incubated
with drug for 4 hr prior to infection. Duplicate wells in a
24-well plate received identical HIV-1 inocula for each drug
concentration tested and for the untreated infected controls.
Uninfected controls and drug toxicity controls were included
in each experiment. All cultures were harvested and cells
were lysed for PCR after either 48 or 72 hr. The entire
experiment was repeated without analysis whenever HIV-1
DNA was amplifiable from input HIV-1 DNA controls (i.e.,
heat-inactivated virus inoculum). Previously characterized
isolates were used as assay standards in each experiment (1,
5).
HIV-1 p24 Antigen-Based Susceptibility Testing. Suscepti-
bility testing based on enzyme-linked immunoassay (Du-
Pont/NEN) of HIV-1 p24 antigen was performed with 7- or
10-day cultures (5). Virus stocks were used in this assay
following infectivity titration by end-point dilution (7).
Quantitative PCR. Cell pellets were lysed in various vol-
umes of lysis buffer (50mM KCl/10mM Tris HCl, pH 8.3/2.5
mM MgCl2/0.5% Nonidet P-40/0.5% Tween 20/0.01% pro-
teinase K) to yield a concentration of 1.2 x 104 cell equiva-
lents/,ul (8). Uniformity of cell lysate DNA concentrations
was confirmed in representative experiments by enhance-
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ment of Hoechst 33258 fluorescence (9) (Mini-Fluorometer,
Hoefer).
A conserved primer pair was synthesized according to the
HIV-1 LAI (formerly BRU) sequence, GenBank accession
no. K02013: 5' primer (sense strand), bases 1889-1908; 3'
primer (antisense strand), bases 2211-2192. The primers were
used to amplify a 323-base-pair fragment of the HIV-1 pol
gene from 1.2 x i05 cell equivalents of lysate by using PCR
(GeneAmp, Cetus) under previously described conditions
(10). Following one cycle of 2 min at 940C, 1 min at 450C, and
1 min at 720C, an additional 29 cycles were performed with 1
min at each of those temperatures. Amplifications were
repeated if HIV-1 DNA was amplifiable from reagent con-
trols.
HIV-1 pol gene amplification products were specifically
detected and quantitated as described (11). Heat-denatured
PCR products were hybridized in a streptavidin-coated mi-
crotiter plate well with both biotinylated capture probe and
horseradish peroxidase (HRP)-labeled detector probe [en-
zyme-linked oligonucleotide solution sanlwich hybridization
assay (ELOSA), DuPont Medical Products, Billerica, MA]
for 60 min at 370C. After extensive washing to remove all
reactants except probe-DNA hybrids, ap HRP chromogen,
tetramethylbenzidine (TMBlue, Transgenic Sciences,
Worcester, MA), was added to each well. The HRP-
catalyzed color development was stopped after 1 hr by
addition of sulfuric acid to 0.65 M. Absorbance (OD) at 450
nm was measured in an automated microtiter plate reader
(SLT Labinstruments, Hillsborough, NC).
A standard curve of HIV-1 DNA copy number was gen-
erated in each PCR by using a dilution series of ACH-2 cells
(National Institutes of Health AIDS Research and Reference
Reagent Program, Rockville, MD) containing one proviral
HIV genome per cell (12). Prior to lysis, 4-fold serial dilutions
of ACH-2 cells were made with HIV-1-seronegative, PHA-
stimulated PBMCs to a final concentration of 1.2 x 104 cells
per gl.
Data Analysis. The standard curve for HIV DNA copy
number was based on a modified log-logit equation: OD = a
+ [(c - a)/{1 +exp[b - d(ln copy number)}]. The constant a
represents background signal from a negative control, de-
fined as twice the OD of a reagent control. The other
constants were determined by computerized estimation (Sys-
tat version 5.1, Systat, Evanston, IL; nonlinear regression
modeling, default options) from the ACH-2 cell dilution series
results in each amplification. The ACH-2 standard curves
each had a corrected r2 2 0.94, and in 85% of the experiments
the r2 was .0.99.
The 50% inhibitory concentration (IC50) was determined
from either PDQ or p24 data by computerized estimation
(Systat, as above) of the median-effect equation: fractional
reduction = 1/[1 + (IC50/drug concentration)'] (13). The
corrected r2 for each PDQ IC50 determination was .0.86,
except for one value that was 0.67.
DNA Sequence Analysis. A 545-base-pair fragment of the
HIV-1 RT gene was PCR amplified from cell lysates by use
of primers from the HIV LAI sequence: 5' primer (sense
strand), bases 2284-2307; 3' primer (antisense strand), bases
2829-2809. Gel-purified PCR products were directly se-
quenced (5).
RESULTS
PDQ measures the amount of HIV-1 DNA synthesized after
in vitro infection relative to a standard curve of HIV-1 DNA
copy number. A curve is constructed in each experiment by
amplification of known numbers of ACH-2 cells diluted with
HIV-1-seronegative donor PBMCs. Amplification results,
under identical reagent and thermal cycling conditions, of
five replicates of each point on such a standard curve are
depicted in Fig. 1A. The 95% confidence intervals (twice the
standard deviation) about the mean amplification yields do
not overlap in the portion of the curve between 16 and 1024
copies (Fig. 1A). The PCR yield plateaus above 1024 copies
of preamplification template.
An initial titration of the infectivity of a virus sample was
done by PDQ to determine conditions necessary for compar-
ison of relative amounts of HIV-1 DNA synthesized in
infected cultures at different drug concentrations. To ensure
adequate quantitation of drug effect, the untreated control
infection copy number must fall on the pre-plateau portion of
the standard curve. An example of a typical PDQ suscepti-
bility test using a primary PBMC coculture supernatant is
depicted in Fig. 1B. Results of duplicate amplifications of
each of two infections at each drug concentration clustered
closely on the standard curve (Fig. 1B), thereby allowing
quantitation of the fractional reduction ofmean copy number
versus AZT concentration (Fig. 2A). Representative median-
effect plots testing previously characterized isolates (1, 5) are
depicted in Fig. 2.
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FIG. 1. Standard curves of relative HIV-1 DNA copy number per
1.2 x 105 cell equivalents were constructed by amplification of a
dilution series of ACH-2 cells; each ACH-2 cell contains a single
proviral genome (12). The PCR product yields were measured by OD
at 450 nm following the ELOSA assay (see Materials and Methods).
(A) Five replicates of each sample of the ACH-2 cell dilution series
(o) are depicted. Error bars indicate twice the standard deviation
above and below the mean [95% confidence interval (CI)]. The actual
data, as well as the coefficient of variation (CV) of replicate ampli-
fications, are shown in the Inset (B) An example of a'PDQ suscep-
tibility experiment which includes: the standard curve (o), the mean
amplification yield of duplicate amplifications (with error bars indi-
cating 95% CIs) of duplicate infections in the absence of AZT (o) or
in the presence of 0.01 ,uM AZT (u), 0.1 IAM AZT (v), 1.0 ,uM AZT
(A&), or 10 AM AZT (i). The virus inoculum was a primary PBMC
coculture supernatant (isolate 349d-3/91). The absolute data and the
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FIG. 2. Median-effect plots from AZT PDQ susceptibility tests. Data for two pairs of clinical isolates previously characterized as
AZT-sensitive [AO12b (1), 14a-4/87 (5)] or AZT-resistant [AO12d (1), 14a-6/89 (5)] are shown. Fractional reduction (A) equals 1 minus the relative
HIV-1 DNA copy number obtained at each drug concentration divided by the relative HIV-1 DNA copy number of untreated infected controls.
Relative HIV-1 DNA copy numbers were calculated using ACH-2 standard curves (Insets) from coamplification of a 4-fold dilution series of
ACH-2 cells.
The AZT IC50 values determined by PDQ susceptibility
testing were supported by two independent methods: HIV-1
p24 antigen-based susceptibility testing using 7- or 10-day
cultures and DNA sequence analysis offour codons of the RT
gene implicated in AZT resistance (2) (Table 1). Isolates
obtained from subjects with minimal or no AZT exposure
[14a-4/87 (5), A012b (1), 45P-6/90] had only wild-type codons
dominating at these positions and PDQ IC50 values s0.003
Table 1. Comparison of AZT PDQ IC50 values with p24 antigen
assay IC50 values and RT sequence
IC50, AM Mutantit RT
Isolate Mo.* PDQ p24 codonst
14a-4/87 0 0.001 0.004 None
A012b 2 0.001 0.006 None
45P-6/90 4 0.003 NT None
27-4/89 6 0.06t 0.024 70
0.06 0.015
349d-3/91 9 0.05t NT 215
100h-3/91 19 0.2f NT 70, 215
14a-6/89 24 0.32 0.64 67, 70, 215, 219
A012d 24 0.15 0.287 67, 70, 215, 219
50-7/89 22 0.19 0.4 67, 70, 215, 219
NT, not tested.
*Months on continuous AZT therapy.
tIndicates which of RT codons 67, 70, 215, and 219 (2) have a
dominant mutant genotype in the isolate.
tPrimary PBMC coculture supernatant was inoculum. Virus stocks
were inocula in other experiments.
,4M (Table 1 and Fig. 2 A and C). Two isolates (349d-3/91,
27-4/89), each obtained after 6-9 months of AZT therapy,
demonstrated a 17- to 60-fold increase in PDQ IC50 relative to
the fully susceptible isolates and had only one of the mutant
RT codons (Table 1 and Fig. 3 A and C). Isolates obtained
after 12-24 months of AZT therapy [14a-6/89 (5), A012d (1),
50-7/89, 100h-3/91] each contained at least the two mutated
RT codons that cause high-level resistance (2), codons 70 and
215 (Table 1). The IC50 values in the PDQ assay were .0.15
,gM for these isolates, 50- to 320-fold greater than for the fully
susceptible isolates (Table 1, Fig. 2 B and D, Fig. 3 B and D).
IC50 values as determined by PDQ or p24 antigen assays were
similar to one another for AZT (Table 1) and for ddI (Table
2). In both assays, the ddI IC50 values were within a narrow
range for isolates from ddI-naive subjects (Table 2).
PDQ was used to titrate the infectivity of supernatant fluids
from 10 unselected HIV-1-positive primary PBMC cocul-
tures to determine the feasibility of directly studying such
fluids. PBMC lysates were found to contain an amount of
HIV-1 DNA adequate for copy-number comparisons within
72 hr of in vitro infection with 9 of these samples. The 10th
supernatant fluid was from a coculture that became HIV-1
p24-positive only after 26 days and was therefore likely to
have a low titer of virus. A lysate of PBMCs infected for 72
hr with this sample required 20 more cycles for positivity.
Two of these primary coculture supernatants (349d-3/91
and 100h-3/91), as well as two others, were studied by PDQ
susceptibility testing (Fig. 3). The PDQ IC50 values were
consistent with RT gene sequencing results (Table 1). How-
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FIG. 3. Median-effect plots from PDQ susceptibility tests (three AZT and one ddl) using supernatants from primary PBMC coculture of four
clinical isolates. The ACH-2 cell standard curve for each experiment is shown (Insets).
not be confirmed by the previously described p24 suscepti-
bility assay because a larger amount of virus inoculum was
needed for that method (5). We did compare the results of
both PDQ and p24 testing of passaged, higher-titer virus to
those ofPDQ testing of primary coculture supernatants. The
IC50 values for these passaged viruses were similar to those
of the coculture supernatant viruses whether determined by
PDQ (isolate 27-4/89, Table 1) or the p24 assay (isolate
27-4/89, Table 1; isolate 50-7/89, Table 2).













All isolates were from subjects who never received ddM.
*Because initial infections yielded too high a copy number when
undiluted cell lysates were amplified, infections were repeated with
a lower multiplicity of infection and the resulting cell lysates were
amplified without dilution.
tBecause initial infections yielded too high a copy number when
undiluted cell lysates were amplified, dilutions of the cell lysates
were amplified.
tPrimary PBMC coculture supernatant was inoculum. Other exper-
iments used virus stocks as inocula.
DISCUSSION
PDQ susceptibility testing has been validated for the isolates
studied by comparison to an HIV-1 p24 antigen-based assay
and by DNA sequencing analyses of RT gene mutations
(Tables 1 and 2). The PDQ method offers significant advan-
tages over other antiretroviral-drug resistance assays. Small
volumes of low-titer virus-containing supernatants from pri-
mary PBMC cocultures, rather than passaged virus, can be
used to test drug sensitivity, thus minimizing the selection
bias of in vitro culture (14). Occasional selection of subpop-
ulations of HIV-1 with passage has been seen (15). Although
p24-antigen based assays can be used on primary PBMC
coculture supernatants, PCR sensitivity should allow PDQ
testing of isolates with very low titers. Isolates with too low
a titer for testing by the 30-cycle amplification described here
may still be testable by PDQ using a greater number of PCR
cycles and a lower range of copy-number standards. How-
ever, the susceptibility of the one virus that required a
50-cycle PDQ infectivity titration to yield signal was not
tested here.
The flexibility of PCR may also obviate the need for
infectivity titration if the IC50 values of all isolates are
determined at similar levels ofamplification yields, within the
range of the standards that permits quantitation. If product
yield from untreated control cells infected with a high mul-
tiplicity of virus falls on the plateau portion of the standard
curve when amplified undiluted, then a dilution of the cell
lysates can be amplified to allow copy-number comparisons
at different drug concentrations. In testing two isolates for
resistance to ddI (14a-4/87 and A012d), the IC50 values
calculated from amplifications of a dilution of cell lysates




















Proc. Natl. Acad. Sci. USA 89 (1992) 3245
those determined from a repeated, lower-multiplicity infec-
tion (Table 2). In other experiments (data not shown), de-
creasing the number of PCR cycles from 30 to 26 also
decreased the amplification yield from an initial plateau-level
copy number to within the range that allows comparisons.
PDQ has allowed quantification of the degree of resistance
of all isolates tested, including highly AZT-resistant isolates.
Such highly AZT-resistant isolates have been reported to
have IC50 values greater than the highest drug concentration
tested in other PBMC-based assays (4, 16). Two theoretical
advantages to PDQ susceptibility testing may explain this
difference. One advantage may result from the short duration
of time needed in culture. AZT-sensitive HIV-1 can be
isolated from an in vitro culture after an extended period,
despite the presence of AZT (17). After extended culture,
virus isolates with differences in both replication rate and
drug susceptibility may appear to have the same IC"0 values.
The early culture end point for PDQ may minimize the risk
of artifactually increased IC50 values for rapidly replicating
viruses that could result from this phenomenon. A second
theoretical advantage ofPDQ testing is specific to agents that
inhibit reverse transcription. It is possible that susceptibility
tests measuring HIV-1 p24 antigen or RNA production in
cultures treated with an RT inhibitor may be less able than
PDQ to distinguish a few infected cells making a large amount
of these virus products from many infected cells. PDQ may
more directly reflect virus spread in such cultures because it
directly measures the reverse-transcribed DNA. The heat-
inactivated virus controls ensure that only newly synthesized
HIV-1 DNA is detected in the PDQ tests. Resistance of input
HIV-1 DNA to DNase has not been noted.
PDQ susceptibility testing has not yet been limited by the
genetic diversity of HIV-1 isolates, although theoretically it
is possible that some isolates may not be amplifiable with the
primers used here. This single, highly conserved primer pair
has amplified HIV-1 DNA from all clinical isolates studied
here, as well as from 57 of 59 HIV-1-seropositive individuals'
PBMCs in an earlier study (10). The ability to rapidly test
HIV-1 isolates from virtually every subject, with minimal
selection pressure from in vitro culture, as well as the
theoretical possibility of fewer artifacts than with other
methods, suggests that PDQ will be useful for epidemiologic
investigation of the pathogenic role of drug-resistant HIV-1.
We thank Martin Hirsch, Victoria Johnson, Joseph Videler,
Lawrence Bechtel, Stephen Boswell, Debra Merrill, Darryld Strick,
Roy Byington, Tim Cooley, Terri Flynn, and Angela Caliendo. Karl
Adler (DuPont Medical Products, Billerica, MA) provided ELOSA
detection reagents. T. Folks contributed the ACH-2 cell line to the
AIDS Reference and Research Reagent Program. AZT was from P.
Furman (Burroughs Wellcome) and ddl was from C. McLaren
(Bristol-Myers Squibb). National Institutes of Health Grants
A107061 and A129193 support J.J.E. and R.T.D., respectively. Some
of the clinical isolates were derived from subjects in National
Institutes of Allergy and Infectious Disease AIDS Clinical Trials
Group protocols.
1. Larder, B. A., Darby, G. & Richman, D. D. (1989) Science 243,
1731-1734.
2. Larder, B. A., Kellum, P. & Kemp, S. D. (1991) AIDS 5,
137-144.
3. St. Clair, M. H., Martin, J. A., Tudor-Williams, G., Bach,
M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D. &
Larder, B. A. (1991) Science 253, 1557-1559.
4. Larder, B. A., Chesebro, B. & Richman, D. D. (1990) Antimi-
crob. Agents Chemother. 34, 436-441.
5. Johnson, V. A., Merrill, D. P., Videler, J. A., Chou, T.-C.,
Byington, R. E., Eron, J. J., D'Aquila, R. T. & Hirsch, M. S.
(1991) J. Infect. Dis. 164, 646-655.
6. McDougal, J. S., Martin, L. S., Cort, S. P., Mozen, M., Helde-
brant, C. M. & Evatt, B. L. (1985) J. Clin. Invest. 76, 875-877.
7. Johnson, V. A. & Byington, R. E. (1990) in Techniques in HIV
Research, eds. Aldovini, A. & Walker, B. D. (Stockton, New
York), pp. 71-76.
8. Kawasaki, E. S. (1990) in PCR Protocols: A Guide to Methods
and Applications, eds. Innis, M. A., Gelfand, D. H., Sninsky,
J. J. & White, T. H. (Academic, San Diego), pp. 146-192.
9. Labarca, C. & Paigen, K. (1980) Anal. Biochem. 102, 344-352.
10. Conway, B., Adler, K. E., Bechtel, L. J., Kaplan, J. C. &
Hirsch, M. S. (1990) J. Acquired Immune Defic. Syndr. 3, 1-6.
11. Conway, B. C. (1990) in Techniques in HIV Research, eds.
Aldovini, A. & Walker, B. D. (Stockton, New York), pp.
40-46.
12. Clouse, K. A., Powell, D., Washington, I., Poli, G., Strebel,
K., Farrar, W., Barstad, D. P., Kovacs, J., Fauci, A. S. &
Folks, T. M. (1989) J. Immunol. 142, 431-438.
13. Chou, T.-C. (1976) J. Theor. Biol. 65, 253-276.
14. Meyerhans, A., Cheynier, R., Albert, J., Seth, M., Kwok, S.,
Asjo, B. & Wain-Hobson, S. (1989) Cell 58, 901-910.
15. Richman, D. D., Guatelli, J. C., Grimes, J., Tsiatis, A. &
Gingeras, T. (1991) J. Infect. Dis. 164, 1075-1081.
16. Japour, A. J., Chatis, P. A., Eigenrauch, H. A. & Crump-
acker, C. S. (1991) Proc. Natl. Acad. Sci. USA 88, 3092-3096.
17. Smith, M. S., Brian, E. L. & Pagano, J. S. (1987) J. Virol. 61,
3769-3773.
Medical Sciences: Eron et al.
